Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Frequently Asked Questions

About the Hemovigilance Module

What is the Hemovigilance Module of NHSN?

The Hemovigilance Module in the Biovigilance Component of NHSN is used to collect data about two types of transfusion-related adverse events: incidents (e.g., errors and near misses) and patient adverse reactions. In addition, transfusion denominators are collected so that adverse event rates can be calculated. The Hemovigilance Module is currently the only module in the Biovigilance Component of NHSN.

Top

Who can participate in the Hemovigilance Module?

Enrollment in the Hemovigilance Module is open to all types of U.S. healthcare facilities where patients receive transfusions. Facility types include acute care hospitals, long-term acute care hospitals, psychiatric hospitals, rehabilitation hospitals, outpatient dialysis centers, ambulatory surgery centers, and long-term care facilities.

Top

Does participation in the NHSN Hemovigilance Module cost anything?

NHSN is free for U.S. healthcare facilities. Facilities are responsible for the personnel and computer equipment necessary to collect and report data to NHSN. Financial support for the operation and maintenance of NHSN is provided by CDC.

Top

Does a facility have to report to CDC, FDA, and the state regulatory authority if they are participating in NHSN?

The NHSN Hemovigilance Module data reported to CDC will be used for public health purposes only. A facility is not required to report NHSN Hemovigilance Module participation to any agency unless required to by state law. Reporting hemovigilance data to CDC does not replace the mandatory or regulatory reporting requirements of FDA, your state, or any other agency that you may be required to report to.

Top

How does a facility benefit from participating in the Hemovigilance Module?

Participants can use the data they enter into NHSN to monitor adverse reactions and quality incidents that occur in their facilities; these data allow facilities to identify areas needing prevention interventions and to tailor and evaluate prevention strategies. Once sufficient data is reported for CDC to publish aggregate surveillance data, facilities will be able to compare their adverse event rates to aggregate data from facilities of similar size and characteristics.

Top

Who has ownership of the Hemovigilance Module data, and who has access to the Hemovigilance Module data?

Each facility owns the data they enter into the Hemovigilance Module. As a requirement of participation in NHSN, facilities agree to share this data with CDC for public health surveillance purposes. In addition, facilities may choose to share their data with entities that have formed Groups in NHSN. CDC will not share facility Hemovigilance Module data with any outside entity.

Top

How does a facility get started in the Hemovigilance Module?

Before beginning the NHSN enrollment process, the facility must determine whether or not they are already enrolled in NHSN for another reporting purpose. If the facility is enrolled, the NHSN Facility Administrator will activate the Biovigilance Component and add users for the Biovigilance Component. If the facility is not enrolled, they will need to begin the NHSN enrollment process. Each potential user should start by completing the required training for the Hemovigilance Module.

Top

How does a facility determine whether or not they are already enrolled in NHSN?

The interested user should contact the infection prevention team or hospital epidemiologist at their facility. More than 4,000 facilities are currently enrolled in NHSN to report central line-associated bloodstream infections (CLABSIs) in the Patient Safety Component of NHSN. Because participation in NHSN is confidential, CDC is unable to publish a list of enrolled facilities. If you are unable to determine whether or not your facility is enrolled in NHSN, contact the NHSN User Support team at CDC.

Top

What training is required for participation in the Hemovigilance Module?

Each facility user is required to review the Biovigilance Component Protocol, the six data collection forms and their accompanying instructions, and training slides for the Hemovigilance Module.

Top

What are the reporting requirements for the Hemovigilance Module in NHSN?

Participating facilities must report all transfusion denominators, all incidents, and all adverse reactions as defined in the Biovigilance Component Protocol for a minimum of twelve months of continuous reporting. In order for CDC to make valid adverse event estimations from the data that facilities report, all facilities must report their data using the same case definitions and reporting requirements.

Top

If a facility is only interested in adverse reactions, do they have to report quality incidents?

Yes, facilities must report both adverse reaction and incident data as a requirement of participation.

Top

What if a facility’s adverse reaction definitions aren’t exactly the same as those defined in the Hemovigilance Module of NHSN?

The case definitions in the Hemovigilance Module are surveillance definitions only and are not intended to be used for clinical care decisions. In order to make valid comparisons of adverse reaction rates, all participants must report their data in the same manner. All facility personnel involved in reporting to the Hemovigilance Module should complete the Hemovigilance Module surveillance trainings to ensure consistent and accurate data reporting.

Top

What if a facility misses a month of data reporting?

If a facility misses a month of data entry, they may still enter data at a later date. Facilities can enter data as far back as January of the year that they enrolled. If a facility misses a month of data collection and are unable to complete the data reporting, that facility’s data may be excluded from aggregate analysis.

Top

Can a facility transfer transfusion adverse event data that they enter into their transfusion software to the NHSN Hemovigilance Module?

CDC is developing a data transfer capability that will enable facilities to transfer data from compatible software systems using data formats called Clinical Document Architecture (CDA). CDA capability for the Hemovigilance Module is expected to be available in 2012.

Top

How does a facility ask questions about the Hemovigilance Module of NHSN?

The NHSN User Support team may be reached by email. Emails sent to this address are monitored regularly during business hours Monday-Friday, and facilities should expect a response within one or two business days.

Top

 
Contact NHSN:
  • Centers for Disease Control and Prevention
    National Healthcare Safety Network
    MS-A24
    1600 Clifton Rd
    Atlanta, GA 30333
  • Contact NHSN@cdc.gov
     
Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd
    Atlanta, GA 30333
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • New Hours of Operation
    8am-8pm ET/Monday-Friday
    Closed Holidays
  • Contact CDC–INFO

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #